LymphomaASCO23
Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies.
The results provide evidence of the real-world effectiveness of ibrutinib in an insured U.S. population.
A new global, multicenter study is enrolling patients with newly diagnosed diffuse large B-cell lymphoma.
Advertisement
Dr. Rutherford and colleagues hypothesized there would be no impact on PFS when imaging was performed less frequently.
Dr. Coombs presented the study and its findings during the 2023 American Society of Clinical Oncology Annual Meeting.
Swetha Kambhampati, MD, of the City of Hope, speaks with Chadi Nabhan, MD, MBA, FACP, about her 2023 ASCO presentation.
Advertisement
The study showed that nivolumab plus AVD improved PFS over brentuximab vedotin plus AVD.
The study compared axicabtagene ciloleucel with standard‑of‑care therapy in patients with relapsed or refractory LBCL.
Dr. Nastoupil discusses findings from TRANSFORM subgroup analyses.
The estimated seven-year EFS rate was 76.7% in patients receiving rituximab maintenance.
Patients received subcutaneous epcoritamab 48 mg with rituximab plus lenalidomide for twelve cycles.
CAR T-cell therapy with lisocabtagene maraleucel resulted in survival benefits for patients with relapsed or refractory.
Lisaftoclax alone or combined with ibrutinib/rituximab demonstrated measurable effects.
These findings suggest that real-world outcomes of brexu-cel are consistent regardless of prior BTK inhibition, brexu-cel.
Targeted induction immunochemotherapy with ibrutinib or lenalidomide and R-MPV is feasible, according to the researchers.
Dr. Dickinson discusses what he sees as the key highlights in lymphoma research during the summer 2023 conference season.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.